Clinical Trials Directory
If you choose to join this study, you will:<ul>
<li>Have tumor tissue from a biopsy sent to a lab for genetic testing</li>
<li>Get an assignment to a study if your tumor tissue has a genetic change that is targeted by one or more of the drugs being tested in this study</li></ul>
We are doing this study to find out if an experimental drug called APL-5125 (the study drug) is a safe and effective for people with select types of gastrointestinal cancer. We are also trying to find the best dose of APL-5125 to use.
We are doing this study to see if the study drugs, domvanalimab and zimberelimab, are safe and effective for treating advanced or metastatic gastroesophageal adenocarcinoma.
We are doing this study to find out if a study drug called sacituzumab govitecan can improve outcomes for patients with high risk, early triple negative breast cancer (TNBC). We want to know if giving this drug in combination with pembrolizumab will work better than pembrolizumab on its own or better than pembrolizumab + capecitabine.
We are doing this study to find out if an experimental drug called ASP2138 (the study drug) is a safe and effective option for people with gastroesophageal junction (GEJ) cancer or metastatic pancreatic cancer.
We are doing this study to find out if an experimental drug called tabelecleucel is effective for the treatment of EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD). We want to know if it is beneficial for people with EBV+PTLD who have received either a solid organ transplant or an allogeneic hematopoietic cell transplant.
We are doing this study to find out if a study drug called belzupacap sarotalocan (bel-sar) is a safe and effective option when it is combined with laser light therapy for people who have a type of eye cancer called an indeterminate lesion (a growth in your eye that is suspected to be melanoma) or choroidal melanoma, which is also known as eye melanoma.
We are doing this study to find out if an experimental drug called MK-4280A (the study drug) is a safe and effective option for people who are diagnosed with different types of solid tumors. We are enrolling Arm A of this study, which is open to people diagnosed with cutaneous squamous cell carcinoma (cSCC).